troglitazone has been researched along with Lymphoma, Large B-Cell, Diffuse in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Lymphoma, Large B-Cell, Diffuse: Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Turturro, F | 1 |
| Driscoll, M | 1 |
| Friday, E | 1 |
| Welbourne, T | 1 |
1 other study available for troglitazone and Lymphoma, Large B-Cell, Diffuse
| Article | Year |
|---|---|
ALK-mediated Na+/H+ exchanger-dependent intracellular alkalinization: does it matter for oncogenesis?
Topics: Alanine; Ammonia; Animals; Cell Division; Cell Line, Tumor; Cell Transformation, Neoplastic; Chroman | 2007 |